Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric pharmacokinetics of cytostatic agents and tyrosine kinase inhibitors in oncology
NL-OMON55747Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of carboplatin, cisplatin, cytarabine, actinomycin D, daunorubicin and 6 more in cancer (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Pharmacokinetic parameters and Covariate effects on pharmacokinetics. Started Feb 2019; status: recruiting.
02
Drugs
carboplatincisplatincytarabineactinomycin Ddaunorubicin
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON55747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55747.